Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional
Official Title: Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome - MesaCAPP
Brief Summary: Multicenter, multinational, randomized, 3-arm, double-blind, phase II clinical study with 2400mg Mesalamine, 1200mg Mesalamine or placebo for prevention of neoplasia in Lynch Syndrome patients for 2 years.